TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Project EAT: Eating and Attitudes in Teens
Brief Summary: Research suggests there is a connection between mood and weight. People who feel stressed or depressed are more likely to be overweight than people who don't have these feelings. Some individuals turn to food to cope, which can lead to gaining too much weight over time. Adolescence is an important time to understand these connections. Patterns of handling stress learned during adolescence set the stage for stress management in adulthood. This study is a randomized controlled pilot study with 60 adolescents who are at-risk for future, chronic obesity. The investigators will test if taking part in a 6-week group program to lower stress and improve mood will be helpful to teens at-risk.


Options:
A: Arm Label: Kids SipSmartER; Type: EXPERIMENTAL; Interventions: Behavioral: Kids SipSmartER | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Kids SipSmartER; Assigned to Arm(s): Kids SipSmartER
B: Arm Label: Learning to Breathe; Type: EXPERIMENTAL; Interventions: Behavioral: Learning to Breathe | Arm Label: Health Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Education | Intervention Type: BEHAVIORAL; Name: Learning to Breathe; Assigned to Arm(s): Learning to Breathe | Intervention Type: BEHAVIORAL; Name: Health Education; Assigned to Arm(s): Health Education
C: Arm Label: Obesity prevention; Type: EXPERIMENTAL; Interventions: Behavioral: Obesity Prevention | Arm Label: Tobacco prevention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Tobacco Prevention | Intervention Type: BEHAVIORAL; Name: Obesity Prevention; Assigned to Arm(s): Obesity prevention | Intervention Type: BEHAVIORAL; Name: Tobacco Prevention; Assigned to Arm(s): Tobacco prevention
D: Arm Label: Intervention arm; Type: EXPERIMENTAL; Interventions: Behavioral: Improve access to the school breakfast program | Arm Label: Comparison arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Improve access to the school breakfast program; Assigned to Arm(s): Intervention arm

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Atopic Dermatitis by a Full-Body Blue Light Device
Brief Summary: Multicentric, placebo-controlled, double-blinded, three-armed, prospective, randomized controlled trial.150 patients diagnosed with atopic dermatitis will be randomized to arm 1 (irradiation for 30min at 415nm wavelength), arm 2 (irradiation for 30min at 450nm wavelength), and arm 3 (irradiation for 30min at low-dose (placebo)). Irradiation will be scheduled 3 times a week for 8 weeks. Patients will be followed up for four weeks after the last irradiation.


Options:
A: Arm Label: A: UVA1; Type: EXPERIMENTAL; Interventions: Procedure: UVA1 phototherapy | Arm Label: B: NB UVB; Type: EXPERIMENTAL; Interventions: Procedure: NB-UVB phototherapy | Intervention Type: PROCEDURE; Name: UVA1 phototherapy; Assigned to Arm(s): A: UVA1 | Intervention Type: PROCEDURE; Name: NB-UVB phototherapy; Assigned to Arm(s): B: NB UVB
B: Arm Label: Blue light at 415nm; Type: EXPERIMENTAL; Interventions: Device: Full Body Blue Light Device | Arm Label: Blue light at 450nm; Type: EXPERIMENTAL; Interventions: Device: Full Body Blue Light Device | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Device: Full Body Blue Light Device | Intervention Type: DEVICE; Name: Full Body Blue Light Device; Assigned to Arm(s): Blue light at 415nm, Blue light at 450nm, Placebo
C: Arm Label: Domestic ion-exchange water softener; Type: EXPERIMENTAL; Interventions: Device: Domestic ion-exchange water softener | Arm Label: Usual hard water supply; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Domestic ion-exchange water softener; Assigned to Arm(s): Domestic ion-exchange water softener
D: Arm Label: Prevalent case of atopic dermatitis; Type: N/A; Interventions: Other: No intervention | Arm Label: Controls; Type: N/A; Interventions: Other: No intervention | Intervention Type: OTHER; Name: No intervention; Assigned to Arm(s): Controls, Prevalent case of atopic dermatitis

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Single-Arm Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Early Stage Relapsing Remitting Multiple Sclerosis
Brief Summary: This is a prospective, multicenter, open-label, single-arm, phase 3b study which evaluates effectiveness and safety of ocrelizumab in participants with early stage RRMS. The study will consist of an open-label treatment period of 192 weeks and follow-up period of at least 48 weeks.

The optional shorter infusion substudy will evaluate the safety of a shorter infusion of ocrelizumab in a subgroup of participants with early stage RRMS enrolled in the main MA30143 study. Approximately 700 patients will be enrolled in the substudy, and will receive additional 600 mg ocrelizumab administered in a shorter time frame.


Options:
A: Arm Label: Laquinimod; Type: EXPERIMENTAL; Interventions: Drug: Laquinimod | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Laquinimod; Assigned to Arm(s): Laquinimod | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Ocrelizumab; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab | Arm Label: Substudy Group 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ocrelizumab | Arm Label: Substudy Group 2; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab, Substudy Group 1, Substudy Group 2
C: Arm Label: Fingolimod (FTY720) 1.25 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo/Fingolimod (FTY720); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Fingolimod (FTY720) 5.0 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): Fingolimod (FTY720) 1.25 mg/day, Fingolimod (FTY720) 5.0 mg/day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Fingolimod (FTY720)
D: Arm Label: Placebo then Evobrutinib 25 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Evobrutinib | Arm Label: Evobrutinib 25 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Evobrutinib | Arm Label: Evobrutinib 75 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Evobrutinib | Arm Label: Evobrutinib 75 mg BID; Type: EXPERIMENTAL; Interventions: Drug: Evobrutinib | Arm Label: Tecfidera; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tecfidera | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Evobrutinib; Assigned to Arm(s): Evobrutinib 75 mg BID | Intervention Type: DRUG; Name: Evobrutinib; Assigned to Arm(s): Evobrutinib 25 mg QD | Intervention Type: DRUG; Name: Evobrutinib; Assigned to Arm(s): Evobrutinib 75 mg QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, Placebo then Evobrutinib 25 mg QD | Intervention Type: DRUG; Name: Tecfidera; Assigned to Arm(s): Tecfidera | Intervention Type: DRUG; Name: Evobrutinib; Assigned to Arm(s): Placebo then Evobrutinib 25 mg QD

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Prospective, Randomized Study to Assess the Effect of Metformin Supplementation on IVF Outcome and Intrafollicular Environment in Patients With Polycystic Ovarian Syndrome Undergoing In Vitro Fertilization/Embryo Transfer
Brief Summary: This study was performed to investigate the effects of metformin on controlled ovarian stimulation (COS), in vitro fertilization (IVF) outcomes, pregnancy outcomes, and comparison of serum and follicular fluid cytokines and hormones in patients with polycystic ovary syndrome (PCOS) undergoing IVF using gonadotropin-releasing hormone(GnRH) antagonist protocol.


Options:
A: Arm Label: Atosiban used before embryo transfer; Type: EXPERIMENTAL; Interventions: Drug: Atosiban | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Atosiban; Assigned to Arm(s): Atosiban used before embryo transfer
B: Arm Label: Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Metformin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin, Placebo
C: Arm Label: M: Metformin P: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Metformin / Placebo treatment for 4 months | Intervention Type: DRUG; Name: Metformin / Placebo treatment for 4 months; Assigned to Arm(s): M: Metformin P: Placebo
D: Arm Label: atosiban; Type: EXPERIMENTAL; Interventions: Drug: atosiban | Arm Label: 0.9% salain; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% saline | Intervention Type: DRUG; Name: atosiban; Assigned to Arm(s): atosiban | Intervention Type: DRUG; Name: 0.9% saline; Assigned to Arm(s): 0.9% salain

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus. A 30-week Randomised, Double-blind, Placebo-controlled Trial
Brief Summary: This trial is conducted in Asia, Europe and North America. The aim of the trial is to compare the effect of semaglutide s.c. 1.0 mg once-weekly versus placebo as add-on to sodium glucose co-transporter-2 inhibitor (SGLT-2i) monotherapy or in combination with either metformin or sulfonylurea on glycaemic control after 30 weeks of treatment in subjects with type 2 diabetes. Subjects will remain on their pre-trial medication.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Dapagliflozin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dapagliflozin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Semaglutide; Type: EXPERIMENTAL; Interventions: Drug: Semaglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Semaglutide; Assigned to Arm(s): Semaglutide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: BI 10773 low dose; Type: EXPERIMENTAL; Interventions: Drug: BI 10773 low dose, Drug: Placebo BI 10773 high dose | Arm Label: BI 10773 high dose; Type: EXPERIMENTAL; Interventions: Drug: BI 10773 high dose, Drug: Placebo BI 10773 low dose | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo BI 10773 high dose, Drug: Placebo BI 10773 low dose | Intervention Type: DRUG; Name: BI 10773 low dose; Assigned to Arm(s): BI 10773 low dose | Intervention Type: DRUG; Name: Placebo BI 10773 high dose; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: BI 10773 high dose; Assigned to Arm(s): BI 10773 high dose | Intervention Type: DRUG; Name: Placebo BI 10773 low dose; Assigned to Arm(s): BI 10773 high dose | Intervention Type: DRUG; Name: Placebo BI 10773 low dose; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Placebo BI 10773 high dose; Assigned to Arm(s): BI 10773 low dose
D: Arm Label: Ertugliflozin, 15 mg; Type: EXPERIMENTAL; Interventions: Drug: Ertugliflozin, Drug: Glycemic Rescue | Arm Label: Ertugliflozin, 5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ertugliflozin, Drug: Placebo, Drug: Glycemic Rescue | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Glycemic Rescue | Intervention Type: DRUG; Name: Ertugliflozin; Assigned to Arm(s): Ertugliflozin, 15 mg, Ertugliflozin, 5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Ertugliflozin, 5 mg, Placebo | Intervention Type: DRUG; Name: Glycemic Rescue; Assigned to Arm(s): Ertugliflozin, 15 mg, Ertugliflozin, 5 mg, Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Supplementation of Vitamin D in Preterm Infants- Monitored Therapy vs Standard Therapy. A Randomized Controlled Trial
Brief Summary: The purpose of this study is to determine wheather the monitored vitamin D (vit D) therapy is safer and more effective than standard therapy in pretrem infants.


Options:
A: Arm Label: monitored group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: monitored vit D supplementation | Arm Label: standard group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: standard vit D supplementation | Intervention Type: DIETARY_SUPPLEMENT; Name: monitored vit D supplementation; Assigned to Arm(s): monitored group | Intervention Type: DIETARY_SUPPLEMENT; Name: standard vit D supplementation; Assigned to Arm(s): standard group
B: Arm Label: Vitamin D 150,000 units once; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: Vitamin D 5000 units daily; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Vitamin D 150,000 units once | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Vitamin D 5000 units daily
C: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: N/A | Arm Label: Calcium plus vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Calcium plus vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Calcium plus vitamin D; Assigned to Arm(s): Calcium plus vitamin D
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D3 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Supplementation of Vitamin D in Preterm Infants- Monitored Therapy vs Standard Therapy. A Randomized Controlled Trial
Brief Summary: The purpose of this study is to determine wheather the monitored vitamin D (vit D) therapy is safer and more effective than standard therapy in pretrem infants.


Options:
A: Arm Label: Intervention group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cholecalciferol | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Cholecalciferol; Assigned to Arm(s): Intervention group | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo group
B: Arm Label: 200 IU/day Vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day | Arm Label: 400 IU/day Vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day | Arm Label: 600 IU/day Vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day | Arm Label: 800 IU/day Vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day; Assigned to Arm(s): 200 IU/day Vitamin D, 400 IU/day Vitamin D, 600 IU/day Vitamin D, 800 IU/day Vitamin D
C: Arm Label: Vitamin D3 100,000 IU; Type: EXPERIMENTAL; Interventions: Drug: Experimental: Vitamin D3 100,000 IU | Arm Label: Vitamin D3 12,000 IU; Type: ACTIVE_COMPARATOR; Interventions: Drug: Active Comparator: Vitamin D3 12,000 IU | Intervention Type: DRUG; Name: Experimental: Vitamin D3 100,000 IU; Assigned to Arm(s): Vitamin D3 100,000 IU | Intervention Type: DRUG; Name: Active Comparator: Vitamin D3 12,000 IU; Assigned to Arm(s): Vitamin D3 12,000 IU
D: Arm Label: monitored group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: monitored vit D supplementation | Arm Label: standard group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: standard vit D supplementation | Intervention Type: DIETARY_SUPPLEMENT; Name: monitored vit D supplementation; Assigned to Arm(s): monitored group | Intervention Type: DIETARY_SUPPLEMENT; Name: standard vit D supplementation; Assigned to Arm(s): standard group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Cluster Randomized Control Trial to Assess the Impact of Active Learning on Child Activity, Attention Control, and Academic Outcomes: The Texas I-CAN Trial
Brief Summary: Background: Active learning is designed to pair physical activity with the teaching of academic content. This has been shown to be a successful strategy to increase physical activity and improve academic performance. The existing designs have confounded academic lessons with physical activity. As a result, it is impossible to determine if the subsequent improvement in academic performance is due to: (1) physical activity, (2) the academic content of the active learning, or (3) the combination of academic material taught through physical activity.

Methods / Design: The Texas I-CAN project is a 3-arm, cluster randomized control trial in which 28 elementary schools were assigned to either control, math intervention, or spelling intervention. As a result, each intervention condition serves as an unrelated content control for the other arm of the trial, allowing the impact of physical activity to be separated from the content. That is, schools that perform only active math lessons provide a content control for the spelling schools on spelling outcomes. This also calculated direct observations of attention and behavior control following periods of active learning.

Discussion: This design is unique in its ability to separate the impact of physical activity, in general, from the combination of physical activity and specific academic content. This, in combination with the ability to examine both proximal and distal outcomes along with measures of time on task will do much to guide the design of future, school-based interventions.


Options:
A: Arm Label: Texas I-CAN Active Math Lessons; Type: EXPERIMENTAL; Interventions: Behavioral: Texas I-CAN! | Arm Label: Texas I-CAN Active Language Arts Lessons; Type: EXPERIMENTAL; Interventions: Behavioral: Texas I-CAN! | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Texas I-CAN!; Assigned to Arm(s): Texas I-CAN Active Language Arts Lessons, Texas I-CAN Active Math Lessons
B: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Active play in after school programs (ASP) | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Active play in after school programs (ASP); Assigned to Arm(s): Intervention group
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: 6 months of healthy physical activity | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: 6 months of healthy physical activity; Assigned to Arm(s): 1
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: CHAM JAM | Arm Label: Wait-Listed Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: CHAM JAM; Assigned to Arm(s): Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Electroacupuncture to Mirabegron on Symptoms of Overactive Bladder in Women Who Have Failed Anti-Cholinergic Therapy
Brief Summary: This study compares electroacupuncture to mirabegron for treatment of overactive bladder (OAB) symptoms in women who have failed treatment with anticholingeric therapy.


Options:
A: Arm Label: acupuncture; Type: EXPERIMENTAL; Interventions: Procedure: acupuncture | Arm Label: Solifenacin plus PFMT; Type: ACTIVE_COMPARATOR; Interventions: Drug: solifenacin, Procedure: PFMT | Intervention Type: PROCEDURE; Name: acupuncture; Assigned to Arm(s): acupuncture | Intervention Type: DRUG; Name: solifenacin; Assigned to Arm(s): Solifenacin plus PFMT | Intervention Type: PROCEDURE; Name: PFMT; Assigned to Arm(s): Solifenacin plus PFMT
B: Arm Label: Acupuncture; Type: EXPERIMENTAL; Interventions: Other: Acupuncture | Arm Label: Sham acupuncture; Type: SHAM_COMPARATOR; Interventions: Other: Sham acupuncture | Intervention Type: OTHER; Name: Acupuncture; Assigned to Arm(s): Acupuncture | Intervention Type: OTHER; Name: Sham acupuncture; Assigned to Arm(s): Sham acupuncture
C: Arm Label: EA; Type: EXPERIMENTAL; Interventions: Other: electroacupncture | Arm Label: Medication; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mirabegron 50 MG [Myrbetriq] | Intervention Type: OTHER; Name: electroacupncture; Assigned to Arm(s): EA | Intervention Type: DRUG; Name: Mirabegron 50 MG [Myrbetriq]; Assigned to Arm(s): Medication
D: Arm Label: Electrical pudendal nerve stimulation; Type: EXPERIMENTAL; Interventions: Behavioral: Electrical pudendal nerve stimulation | Arm Label: PFM training with Transvaginal ES; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: PFM training, Behavioral: Transvaginal ES | Intervention Type: BEHAVIORAL; Name: Electrical pudendal nerve stimulation; Assigned to Arm(s): Electrical pudendal nerve stimulation | Intervention Type: BEHAVIORAL; Name: PFM training; Assigned to Arm(s): PFM training with Transvaginal ES | Intervention Type: BEHAVIORAL; Name: Transvaginal ES; Assigned to Arm(s): PFM training with Transvaginal ES

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Electroacupuncture to Mirabegron on Symptoms of Overactive Bladder in Women Who Have Failed Anti-Cholinergic Therapy
Brief Summary: This study compares electroacupuncture to mirabegron for treatment of overactive bladder (OAB) symptoms in women who have failed treatment with anticholingeric therapy.


Options:
A: Arm Label: Group 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Structured training and leaflet | Arm Label: Group 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Structured training | Arm Label: Group 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Leaflet | Arm Label: Group 4; Type: SHAM_COMPARATOR; Interventions: Behavioral: Control Group | Intervention Type: BEHAVIORAL; Name: Structured training and leaflet; Assigned to Arm(s): Group 1 | Intervention Type: BEHAVIORAL; Name: Structured training; Assigned to Arm(s): Group 2 | Intervention Type: BEHAVIORAL; Name: Leaflet; Assigned to Arm(s): Group 3 | Intervention Type: BEHAVIORAL; Name: Control Group; Assigned to Arm(s): Group 4
B: Arm Label: exercise; Type: EXPERIMENTAL; Interventions: Behavioral: specific training program | Arm Label: control; Type: ACTIVE_COMPARATOR; Interventions: Other: standard | Intervention Type: OTHER; Name: standard; Assigned to Arm(s): control | Intervention Type: BEHAVIORAL; Name: specific training program; Assigned to Arm(s): exercise
C: Arm Label: Physical & Behavioral Therapy Group; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Therapy (PT) and Behavioral Therapy (BT) | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical Therapy (PT) and Behavioral Therapy (BT); Assigned to Arm(s): Physical & Behavioral Therapy Group
D: Arm Label: EA; Type: EXPERIMENTAL; Interventions: Other: electroacupncture | Arm Label: Medication; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mirabegron 50 MG [Myrbetriq] | Intervention Type: OTHER; Name: electroacupncture; Assigned to Arm(s): EA | Intervention Type: DRUG; Name: Mirabegron 50 MG [Myrbetriq]; Assigned to Arm(s): Medication

Answer: D